CD47, a multi-facetted target for cancer immunotherapy

Show simple item record

dc.contributor.author Wiersma, Valerie R -
dc.contributor.author van Bommel, Peter E -
dc.contributor.author de Bruyn, Marco -
dc.contributor.author Helfrich, Wijnand -
dc.contributor.author Bremer, Edwin -
dc.date.accessioned 2017-04-28T09:10:55Z
dc.date.available 2017-04-28T09:10:55Z
dc.date.issued 2015 -
dc.identifier.citation Valerie R, Wiersma ; Peter E, van Bommel ; Marco, de Bruyn ; Wijnand, Helfrich ; Edwin, Bremer. CD47, a multi-facetted target for cancer immunotherapy. Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2015, 6, p. 417-431 -
dc.identifier.issn 1768-3262
dc.identifier.uri http://hdl.handle.net/2042/62150
dc.description.abstract CD47 is a ubiquitously expressed immunoregulatory protein best known for its so-called 'don't eat me' function that prevents phagocytic removal of healthy cells by the immune system. Many types of cancer present high levels of this don't eat me signal on their surface, thereby disrupting anti-cancer immune responses. Based on this observation, CD47 has become a prominent target in the field of cancer immunotherapy. Indeed, pre-clinical studies have shown therapeutic benefit of anti-CD47 antibodies in solid cancers and most notably B-cell malignancies. However, CD47 is also involved in various other important cellular processes, such as angiogenesis, cancer cell death and regulation of T-cell immunity, which can be modulated via interactions with thrombospondin-1. The therapeutic outcome of CD47-targeted immunotherapy therefore relies on the combined effects of all these processes. Here we will review the various physiological functions of CD47 and their implications in cancer biology. Further, we will review ongoing efforts and provide perspectives for exploiting CD47 as an immunotherapeutic target in cancer. en
dc.language.iso en -
dc.publisher Jean-Loup Huret (Editor-in-Chief) -
dc.relation Atlas of Genetics and Cytogenetics in Oncology and Haematology ; http://AtlasGeneticsOncology.org/Deep/CD47TumAndImmunoID20140.html -
dc.relation.ispartofseries Atlas of Genetics and Cytogenetics in Oncology and Haematology
dc.rights Open access resource - terms and conditions : http://irevues.inist.fr/utilisation -
dc.subject CD47 en
dc.subject Signal regulatory protein α (SIRP α) en
dc.subject Thrombospondin-1 (TSP-1) en
dc.subject cancer (immune) therapy en
dc.subject phagocytosis en
dc.subject angiogenesis en
dc.subject.classification Deep Section en
dc.subject.mesh Humans en
dc.subject.mesh Mice en
dc.subject.mesh FeCell Line, Tumor en
dc.subject.mesh Antigens, CD47/*immunology en
dc.subject.mesh Mice, Inbred C57BL en
dc.subject.mesh Prognosis en
dc.subject.mesh Phagocytosis/immunology en
dc.subject.mesh Middle Aged en
dc.subject.mesh Mice, Nude en
dc.subject.mesh Cell Proliferation en
dc.subject.mesh Aged en
dc.subject.mesh Adult en
dc.subject.mesh Young Adult en
dc.subject.mesh Xenograft Model Antitumor Assays en
dc.subject.mesh Up-Regulation en
dc.subject.mesh Transplantation, Heterologous en
dc.subject.mesh Thrombospondin 1/*metabolism en
dc.subject.mesh Signal Transduction en
dc.title CD47, a multi-facetted target for cancer immunotherapy en
dc.type Article -
dc.contributor.affiliation University of Groningen, University Medical Center Groningen (UMCG), Department of Surgery, Translational Surgical Oncology, Groningen, (The Netherlands) -
dc.contributor.affiliation University of Groningen, University Medical Center Groningen (UMCG), Department of Obstetrics, Gynecology, Groningen, (The Netherlands) -
dc.contributor.affiliation Exeter University Medical School, Devon, (UK) -
dc.identifier.doi https://doi.org/10.4267/2042/62150


Files in this item

PDF 10-2014-CD47TumAndImmunoID20140.pdf 617.2Kb

This item appears in the following Collection(s)

Show simple item record





Advanced Search